Matthew Stanton, CFA
Stock Analyst at Jefferies
(0.51)
# 3,973
Out of 4,356 analysts
19
Total ratings
42.9%
Success rate
-19.1%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGEN Repligen | Maintained: Hold | $135 → $142 | $123.95 | +14.56% | 7 | May 5, 2026 | |
| AZTA Azenta | Maintained: Buy | $42 → $35 | $22.88 | +52.97% | 5 | Apr 1, 2026 | |
| CYRX Cryoport | Maintained: Hold | $6.5 → $8 | $15.69 | -49.01% | 4 | Aug 6, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintained: Buy | $10 | $4.80 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $1.15 | n/a | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiated Coverage: Buy | $22 | $24.92 | n/a | 1 | Apr 4, 2024 |
Repligen
May 5, 2026
Maintained: Hold
Price Target: $135 → $142
Current: $123.95
Upside: +14.56%
Azenta
Apr 1, 2026
Maintained: Buy
Price Target: $42 → $35
Current: $22.88
Upside: +52.97%
Cryoport
Aug 6, 2025
Maintained: Hold
Price Target: $6.5 → $8
Current: $15.69
Upside: -49.01%
Maravai LifeSciences Holdings
Mar 18, 2025
Maintained: Buy
Price Target: $10
Current: $4.80
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $1.15
Upside: n/a
BioLife Solutions
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $22
Current: $24.92
Upside: n/a